Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650184 | 0.97 | MAPT (0.71) | MAPTSMN1; SMN2LMNANPSR1TSHR | |
| SCHEMBL694044 | 0.95 | MAPT (0.74) | MAPTSMN1; SMN2LMNANPSR1TSHR | |
| SCHEMBL23005300 | 0.94 | CYP2C19 (0.62) | MAPTSMN1; SMN2LMNANPSR1TSHR | |
| SCHEMBL25233963 | 0.85 | RAB9A (0.89) | MAPTSMN1; SMN2LMNANPSR1TSHR | |
| SCHEMBL11729220 | 0.81 | PTPN1 (0.64) | MAPTSMN1; SMN2LMNANPSR1MEN1 | |
| SCHEMBL16669620 | 0.81 | RAB9A (0.86) | MAPTSMN1; SMN2LMNANPSR1CYP2C19 | |
| SCHEMBL16589431 | 0.80 | ALDH1A1 (0.68) | MAPTSMN1; SMN2LMNANPSR1TSHR | |
| SCHEMBL7863859 | 0.80 | PTPN1 (0.66) | MAPTLMNANPSR1CYP2C19MEN1 | |
| SCHEMBL5205624 | 0.79 | NPC1 (0.69) | MEN1KMT2ARAB9ANPC1HPGD | |
| SCHEMBL125695 | 0.79 | PTPN1 (0.89) | MAPTSMN1; SMN2LMNANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3931183-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | VENTHERA, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2022042657-A1 | COMPOUNDS AND METHODS OF USE | Ferro Therapeutics, Inc. (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-114008024-A | Compounds having iron death inducing activity and methods of using the same | 费罗治疗公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3931183-A1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | Ferro Therapeutics, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | MAPT 4231/4885SMN1; SMN2 2416/4885LMNA 2800/4885 |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | MAPT 4231/4885SMN1; SMN2 2416/4885LMNA 2800/4885 |
| US-11040964-B2 | Compounds and methods of use | AIFM2, GPX4, GPX1 | MAPT 4231/4885SMN1; SMN2 2416/4885LMNA 2800/4885 |
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, SLC40A1, GPX4 | MAPT 3920/4885SMN1; SMN2 2634/4885LMNA 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.